Company intelligence / Profile preview
MRM Health
Ghent, Belgiummrmhealth.com ↗
- Ownership
- Private
- Employees
- ~33
- Development stage
- Other
01
Overview
MRM Health has demonstrated positive Phase 2a results for its lead live biotherapeutic consortium MH002 in ulcerative colitis and pouchitis. The company’s proprietary CORAL® technology enables the design and scalable manufacturing of optimized microbial consortia as single drug substances. Additional programs are advancing through preclinical development targeting immuno-oncology, autoimmune disorders, metabolic dysfunction-associated steatotic liver disease (MASH), spondylarthritis, and Parkinson’s disease.
- Therapeutic areas
- GastroenterologyRheumatologyImmunologyNeurology
- Modalities
- Live biotherapeutic product therapyMicrobial therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
IFF/DuPont Nutrition BiosciencesVIBEvonik
Beyond the preview
Go deeper on MRM Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRM Health.